Intelligence Feed event · Macro · 2026-09-05

    Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint

    Question

    Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint

    Direct answer

    Topline results from Novartis' pivotal Phase 3 HORIZON trial showed pelacarsen failed to significantly reduce major adverse cardiovascular events in patients with elevated Lp(a). Royalty Pharma confirmed it anticipates recovering its full $500 million investment principal along with modest returns, though future royalty growth upside from the asset is eliminated.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-05
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint”, revision 1, evidence through 2026-09-05. https://marketontology.com/market-events/2026-09-05/novartis-phase-3-pelacarsen-cardiovascular-trial-misses-primary-endpoint-0bc179

    MACRO
    Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint
    Topline results from Novartis' pivotal Phase 3 HORIZON trial showed pelacarsen failed to significantly reduce major adverse cardiovascular events in patients with elevated Lp(a). Royalty Pharma confirmed it anticipates recovering its full $500 million investment principal along with modest returns, though future royalty growth upside from the asset is eliminated.
    RPRXNVS
    Impact
    75
    SEP 5
    SIG
    88%
    RPRXNVS
    Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint
    Topline results from Novartis' pivotal Phase 3 HORIZON trial showed pelacarsen failed to significantly reduce major adverse cardiovascular events in patients with elevated Lp(a). Royalty Pharma confirmed it anticipates recovering its full $500 million investment principal along with modest returns, though future royalty growth upside from the asset is eliminated.
    → Phase 3 clinical trial failures eliminate projected royalty cash flows and downstream drug commercialization revenue for licensing partners.
    Impact
    Topline results from Novartis' pivotal Phase 3 HORIZON trial showed pelacarsen failed to significantly reduce major adverse cardiovascular events in patients with elevated Lp(a). Royalty Pharma confirmed it anticipates recovering its full $500 million investment principal along with modest returns, though future royalty growth upside from the asset is eliminated.
    Affected
    RPRXNVS
    Transmission
    Phase 3 clinical trial failures eliminate projected royalty cash flows and downstream drug commercialization revenue for licensing partners.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    RPRXelimination of future pipeline royalty cash flow upsideWatch1-4wRoyalty Pharma announced Novartis Phase 3 HORIZON trial failed primary endpoint.
    NVSloss of projected late-stage cardiovascular drug franchise revenueDown1-5dPhase 3 HORIZON trial failed primary endpoint of reducing cardiovascular events.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month